Cargando…

The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in the US, and it is expected to be the second leading cause of cancer deaths by 2030. The lack of effective early screening tests and alarming symptoms with early undetectable micro-metastasis at the time of presen...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsayed, Marwa, Abdelrahim, Maen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067364/
https://www.ncbi.nlm.nih.gov/pubmed/33917380
http://dx.doi.org/10.3390/biomedicines9040389
_version_ 1783682785616068608
author Elsayed, Marwa
Abdelrahim, Maen
author_facet Elsayed, Marwa
Abdelrahim, Maen
author_sort Elsayed, Marwa
collection PubMed
description Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in the US, and it is expected to be the second leading cause of cancer deaths by 2030. The lack of effective early screening tests and alarming symptoms with early undetectable micro-metastasis at the time of presentation play a vital role in the high death rate from pancreatic cancer. In addition to this, the low mutation burden in pancreatic cancer, low immunological profile, dense tumorigenesis stroma, and decreased tumor sensitivity to cytotoxic drugs contribute to the low survival rates in PDAC patients. Despite breakthroughs in chemotherapeutic and immunotherapeutic drugs, pancreatic cancer remains one of the solid tumors that exhibit meager curative rates. Therefore, researchers must dedicate more effort to understanding the pathology and immunological behavior of PDAC, in addition to properly utilizing more advanced screening modalities and new therapeutic agents. In our review, we focus mainly on the latest updates from clinical guidelines and novel therapies that have been recently investigated or are under investigation for PDAC. We used PubMed as a search tool for finding original research articles addressing the latest developments in diagnosing and treating PDAC. Additionally, we also used the clinical trials published on clinicaltrialsgov as sources for our data.
format Online
Article
Text
id pubmed-8067364
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80673642021-04-25 The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies Elsayed, Marwa Abdelrahim, Maen Biomedicines Review Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in the US, and it is expected to be the second leading cause of cancer deaths by 2030. The lack of effective early screening tests and alarming symptoms with early undetectable micro-metastasis at the time of presentation play a vital role in the high death rate from pancreatic cancer. In addition to this, the low mutation burden in pancreatic cancer, low immunological profile, dense tumorigenesis stroma, and decreased tumor sensitivity to cytotoxic drugs contribute to the low survival rates in PDAC patients. Despite breakthroughs in chemotherapeutic and immunotherapeutic drugs, pancreatic cancer remains one of the solid tumors that exhibit meager curative rates. Therefore, researchers must dedicate more effort to understanding the pathology and immunological behavior of PDAC, in addition to properly utilizing more advanced screening modalities and new therapeutic agents. In our review, we focus mainly on the latest updates from clinical guidelines and novel therapies that have been recently investigated or are under investigation for PDAC. We used PubMed as a search tool for finding original research articles addressing the latest developments in diagnosing and treating PDAC. Additionally, we also used the clinical trials published on clinicaltrialsgov as sources for our data. MDPI 2021-04-06 /pmc/articles/PMC8067364/ /pubmed/33917380 http://dx.doi.org/10.3390/biomedicines9040389 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Elsayed, Marwa
Abdelrahim, Maen
The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies
title The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies
title_full The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies
title_fullStr The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies
title_full_unstemmed The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies
title_short The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies
title_sort latest advancement in pancreatic ductal adenocarcinoma therapy: a review article for the latest guidelines and novel therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067364/
https://www.ncbi.nlm.nih.gov/pubmed/33917380
http://dx.doi.org/10.3390/biomedicines9040389
work_keys_str_mv AT elsayedmarwa thelatestadvancementinpancreaticductaladenocarcinomatherapyareviewarticleforthelatestguidelinesandnoveltherapies
AT abdelrahimmaen thelatestadvancementinpancreaticductaladenocarcinomatherapyareviewarticleforthelatestguidelinesandnoveltherapies
AT elsayedmarwa latestadvancementinpancreaticductaladenocarcinomatherapyareviewarticleforthelatestguidelinesandnoveltherapies
AT abdelrahimmaen latestadvancementinpancreaticductaladenocarcinomatherapyareviewarticleforthelatestguidelinesandnoveltherapies